CNSP News and Press, CNS Pharmaceuticals Inc. From 02/23/23

Immunotherapy is one of the newest cancer treatment options that has made it possible for physicians to target and treat cancer more effectively. This treatment works by helping a patient’s immune system to kill cancer cells rather than using pharmaceuticals or radiation therapy to dire...

University of Waterloo researchers have created a tool that leverages artificial intelligence (AI) to personalize breast cancer treatment. The development of machine learning and artificial intelligence technology in recent years has been a game changer , allowing professionals in various in...

The American Cancer Society estimates that around 9,910 children under the age of 15 will be diagnosed with cancer this year. Pediatric cancer is the second largest cause of death in children up to 14 years of age in the United States, and the disease is expected to take the lives of 1,040 ch...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that enrollment is continuing in its ongoing global trial evaluating Berubicin for t...

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM PR Newswire Enrollment continuing to progress toward an interim analysis, planned when 30-50% of subjects reach the primary e...

Glioblastoma is an aggressive type of brain and spinal cord cancer that typically affects brain tissues, usually the frontal and temporal lobes of the brain. Treatment options for the debilitating brain cancer tend to lower white blood cell counts for six months to a year, which inadvertently i...

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported that 67 patients have enrolled in the potentially pivotal phase 2 globally cited clinical study comparing drug candidate Berubicin’s effectiveness to second-line standard-of-care chemotherapy drug Lomustine. “The  company pl...

Proteins come in various shapes , making it hard to determine how they move and, in turn, how they function. A study conducted by researchers at the Karolinska Institute has discovered a new target for brain tumors through the use of computer simulations. Laura Orellana , a biophysicist at ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The ...

The American Cancer Society Journals estimates that there will be 1.9 million additional cancer diagnoses and 609,820 million cancer deaths this year. The deadly disease affects tens of millions of people globally and... Read more » NOTE TO INVESTORS:  The latest news and upd...